Is Baxter International Inc. (BAX) a Buy, Sell, or Hold?
Baxter International Inc.
NYSE:BAX
$22.15 USD
$0.35 (1.61%)
- Volume
- 3.78M
- Average Volume
- 7.16M
- Market Capitalization
- $11.44B
- P/E Ratio
- -10.55
- Dividend Yield
- 0.90%
- Price Target
- $20.00
- Year High
- $29.35
- Year Low
- $15.73
- Day High
- —
- Day Low
- —
- Payout Ratio
- $-0.24
- Current Ratio
- $1.85
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Andrew Hider |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Current Symbol | BAX |
| CUSIP | 071813109 |
| CIK | 0000010456 |
| Web | https://www.baxter.com |
| Phone | 224 948 2000 |
| Currency | USD |
| Employees | 37500 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.60 |
| Payout Ratio | -0.24 |
| Current Ratio | 1.85 |
| Quick Ratio | 1.23 |
| Cash Ratio | 0.55 |
Sales & Book Value
| Annual Sales | $11.24B |
| Price / Sales | 1.01 |
| Cash Flow | 1.39 |
| Price / Cash Flow | 16.02 |
| Price / Book | 1.89 |
Price Target and Rating
| Average Stock Price Forecast | $20.00 |
| High Stock Price Forecast | $27.00 |
| Low Stock Price Forecast | $19.00 |
| Forecast Upside/Downside | 10.75% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 36 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.75 |
| Trailing P/E Ratio | -10.55 |
| PEG Ratio | 0.15 |
| P/E Growth | 0.15 |
| Net Income | $-957M |
| Net Margin | -9.70% |
| Pretax Margin | -4.49% |
| Return on Equity | -16.43% |
| Return on Assets | -5.53% |
Financials Score
| AltmanZ Score | 2.19 |
| Piotroski Score | 5.00 |
| Working Capital | 3.15B |
| Total Assets | 19.85B |
| Ebit | -233M |
| Market Cap | 11.66B |
| Total Liabilities | 13.83B |
Poll Results
About Baxter International Inc. (NYSE:BAX) Stock
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devic ... es vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap
2026-07-15 07:45:54
Both AbbVie (NYSE:ABBV | ABBV Price Prediction) and Baxter International (NYSE:BAX) flashed the same technical signal this month: a golden cross, where the 50-day moving average pushed above the 200-day.
Baxter to Host Second-Quarter 2026 Financial Results Conference Call for Investors
2026-07-09 16:10:00
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its second-quarter 2026 financial results on Thursday, July 30, 2026, at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://events.q4inc.com/attendee/167756971 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.bax.
2026-06-22 10:00:00
Baxter International Inc. (NYSE: BAX), a global medtech leader, today published its newly renamed [url="]2025 Sustainability Report[/url], highlighting the comp
2026-06-22 09:00:00
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today published its newly renamed 2025 Sustainability Report, highlighting the company's progress and refreshed approach to advancing a sustainable and responsible business model. “As we shape Baxter's next chapter, our focus remains clear: making a meaningful difference for patients, customers and communities while working to create long‑term value for all stakeholders,” said Andrew Hider, presiden.
Baxter's Unit Synovis MCA to Lead Global Rollout of the SHIYA Platform
2026-06-19 11:25:38
BAX gains as Synovis MCA signs a multi-year deal to commercialize MediThinQ's SHIYA 3D surgical visualization platform worldwide.
Reasons to Retain Baxter International Stock in Your Portfolio for Now
2026-06-16 15:16:09
BAX is pursuing a broad turnaround as innovation, resilient demand, and AI integration support recovery despite regulatory risks and margin pressure.
2026-06-09 14:42:10
Baxter International Inc. (BAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
2026-05-13 16:40:44
Baxter International Inc. (BAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Frequently Asked Questions
-
What is the current Baxter International Inc. (BAX) stock price?
-
Baxter International Inc.(NYSE:BAX) stock price is $22.15 in the last trading session. During the trading session, BAX stock reached the peak price of $29.35 while $15.73 was the lowest point it dropped to. The percentage change in BAX stock occurred in the recent session was 1.61% while the dollar amount for the price change in BAX stock was $0.35.
-
BAX's industry and sector of operation?
-
The NYSE listed BAX is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector.
-
Who are the executives of BAX?
-
Steven Wallace | President of Advanced Surgery & Commercial Excellence
Anita A. Zielinski | Senior Vice President, Interim Chief Financial Officer, Chief Accounting Officer & Controller
Cynthia Carlisle | Executive Vice President & Chief Human Resources Officer
Maria Soriano | Group President of Infusion Therapies & Platforms
Stacey Eisen | SVP, Chief Communications Officer & Corporate Marketing and President of Baxter Foundation -
How many employees does BAX have?
-
Number of BAX employees currently stands at 37500. BAX operates from One Baxter Parkway, Deerfield, IL 60015, US.
-
Link for BAX official website?
-
Official Website of BAX is: https://www.baxter.com
-
How do I contact BAX?
-
BAX could be contacted at phone #224 948 2000 and can also be accessed through its website. BAX operates from One Baxter Parkway, Deerfield, IL 60015, US.
-
How many shares of BAX are traded daily?
-
The average number of BAX shares traded daily for last 3 months was 7.16M.
-
What is the market cap of BAX currently?
-
The market value of BAX currently stands at $11.44B with its latest stock price at $22.15